These results are consistent with the meta-analysis published by Burotto et al, which reported similar effectiveness and security of afatinib, erlotinib, and gefitinib, while used as first-line therapy for patients with EGFR-mutated NSCLC [16]. Here, EGFR is linked to non-small cell lung carcinoma.